You are hereDecember 22, 2020
Augmenting HSPC Regeneration with Sirolimus
The results of a new study led by Xingmin Feng (NHLBI, National Institutes of Health, Bethesda, MD, USA) provide further evidence that sirolimus treatment can accelerate the recovery of hematopoietic stem and progenitor cells (HSPCs) following hematopoietic stress and reduce both reactive oxygen species levels and DNA damage. Overall, Lin et al. suggest that sirolimus administration might represent a clinically-relevant means to treat/prevent hematopoietic injury. See STEM CELLS for all the details!